Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped”, a special commemorative book from The Boston Globe. Order now.

Eli Lilly still hopeful on Alzheimer’s drug

Lilly’s Alzheimer’s drug is the second this year to fail; the other was from Pfizer and Johnson & Johnson.

Associated Press/File 2012

Lilly’s Alzheimer’s drug is the second this year to fail; the other was from Pfizer and Johnson & Johnson.

Continue reading below

Eli Lilly & Co., still hopeful about an experimental Alzheimer’s drug despite two disappointing studies, said it will do another one, probably in the third quarter of 2013 and focusing on patients with mild Alzheimer’s. This year, two clinical trials showed solanezumab did not significantly improve either the cognition or daily functioning of people with mild and moderate forms of the disease. But when those with mild Alzheimer’s were separated out, the drug was shown to significantly slow their decline in cognition.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com